"Lymphoma, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
| Descriptor ID |
D016399
|
| MeSH Number(s) |
C04.557.386.480.750 C15.604.515.569.480.750 C20.683.515.761.480.750
|
| Concept/Terms |
Lymphoma, T-Cell- Lymphoma, T-Cell
- Lymphoma, T Cell
- T-Cell Lymphoma
- Lymphomas, T-Cell
- T Cell Lymphoma
- T-Cell Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell".
This graph shows the total number of publications written about "Lymphoma, T-Cell" by people in this website by year, and whether "Lymphoma, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 4 | 1 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell" by people in Profiles.
-
Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism. Apoptosis. 2022 08; 27(7-8):606-618.
-
Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis. Environ Toxicol. 2022 Jun; 37(6):1445-1457.
-
Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):431-438.
-
Nimbolide induces cell death in T lymphoma cells: Implication of altered apoptosis and glucose metabolism. Environ Toxicol. 2021 Apr; 36(4):628-641.
-
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020 09 08; 4(17):4256-4266.
-
A Rare Case of T-Cell Lymphoma Presenting With Bilateral Nephrolithiasis and Acute Renal Failure. Urology. 2020 12; 146:222-224.
-
Multifaceted effects of soluble human CD6 in experimental cancer models. J Immunother Cancer. 2020 03; 8(1).
-
Lysophosphatidic acid promotes survival of T lymphoma cells by altering apoptosis and glucose metabolism. Apoptosis. 2020 02; 25(1-2):135-150.
-
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.
-
Drug induced pseudolymphoma. Semin Diagn Pathol. 2018 Jul; 35(4):247-259.